Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces mortality and morbidity in patients with chronic heart failure (HF). However, the clinical implication of SGLT2i therapy in patients with acute decom-pensated HF remains uncertain. We prospectively studied 86 type 2 diabetic mellitus (T2DM) patients (71.8 ± 12.1 years, 55 men) who were hospitalized for acute decompensated HF and received SGLT2i during the index hospitalization. Among the patients, 56 continued SGLT2i at discharge and 30 did not. The continued group ex-perienced fewer HF re-hospitalizations than the discontinued group (24% versus 39%, P = 0.008) with a hazard ratio of 0.29 (95% confidence interval 0.10-0.85) adjusted for other significant potential confounders. In conclusion, long-term SGLT2i therapy might prevent unplanned HF re-hospitalization in patients with T2DM and acute decompensated HF.
CITATION STYLE
Nakagaito, M., Imamura, T., Joho, S., Ushijima, R., Nakamura, M., & Kinugawa, K. (2021). Efficacy of continuing sglt2 inhibitors on outcomes in patients with acute decompensated heart failure. International Heart Journal, 62(4), 885–890. https://doi.org/10.1536/ihj.21-022
Mendeley helps you to discover research relevant for your work.